Hormone-Dependent Tumours of the Kidney

Bloom, H. J. G.; Dukes, C. E.; Mitchley, B. C. V.

doi:10.1038/bjc.1963.81

Cited by 67 publications

(15 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When testosterone was substituted for the progestin, the patient improved quite dramatically, returning rapidly to good health without evidence of active disease for 3 years (Case D.W.) (Bloom and Wallace, 1964). Although tumour stimulation by hormones was not observed in experiments with the strain of transplanted hamster renal carcinoma used in our laboratories (Bloom et al, 1963a), an increase in tumour growth rate was reported by Kirkman (1959) when testosterone was administered to stilboestrol-treated animals bearing the transplanted " oestrogen-dependent" strain of tumour.…”

Section: Sexmentioning

confidence: 58%

“…Because a combination of cortisone and Provera produced a more striking inhibitory effect on the transplantable hamster renal tumour than cortisone alone (Bloom et al, 1963a), both hormones were tried together in a few patients who failed to respond to Provera but without success. Significant tumour regression 262 PROVERA TREATMENT OF METASTATIC RENAL CANCER was not observed with corticosteroids or with stilboestrol.…”

Section: Discussionmentioning

confidence: 99%

“…Provera combined with cortisone, but not alone, markedly reduced the growth rate of " independent " tumour transplants (Bloom et al, 1963a). Actual tumour regression was achieved by orchiectomy and this action was nullified by the administration of oestradiol (Bloom et al, 1963b).…”

Section: Provera Treatment Of Metastatic Renal Cancermentioning

confidence: 95%

“…In previous publications we have drawn attention to clinical, pathological and experimental evidence in support of the concept of a hormonal background to carcinoma of the kidney, and to the possibility of achieving worthwhile palliation in a small proportion of very advanced cases by the administration of gonadal hormones, chiefly progestins (Bloom et al, 1963a(Bloom et al, 1963bBloom and Wallace, 1964;Bloom, 1964Bloom, , 1967. Such agents appear to be not only more successful in controlling the disease than cytotoxic drugs, but are also remarkably free from serious side-effects following prolonged administration in large doses.…”

Section: Provera Treatment Of Metastatic Renal Cancermentioning

confidence: 99%

“…A transplantable renal adenocarcinoma of the golden hamster, induced by prolonged oestrogen administration (Matthews et al, 1947;Kirkman, 1959;Horning, 1956), has been employed as an experimental model with which to try and find hormonal agents which may be of value in the treatment of advanced renal cancer in man (Bloom et al, 1963a.…”

Section: Provera Treatment Of Metastatic Renal Cancermentioning

confidence: 99%

See 4 more Smart Citations

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer

Bloom¹

1971

Br J Cancer

Self Cite

View full text Add to dashboard Cite

SUMMARY.-Eighty patients with advanced metastatic renal cancer have been treated with hormones, chiefly medroxyprogesterone acetate (Provera). This progestational compound is remarkably free from side-effects and can be given in high dosage for long periods without serious complications. Ninety per cent of cases had multiple metastases: in 76% more than one organ was involved and nearly 50% were seriously ill or " terminal ".Subjective improvement occurred in at least 55%. BETWEEN 75% and 80% of patients treated for renal cell carcinoma will die within 10 years of their primary treatment, the majority with distant metastases. In a few of these cases the natural history of the disease will be unusual. For example, growth of metastases may be exceptionally slow or, following removal of a solitary lesion, the patient may live for a number of years without further recurrence. Very rarely spontaneous regression of pulmonary deposits may occur. For the vast majority of cases, however, the onset of clinical metastases heralds death within a year or two. The treatment of advanced renal cancer with cytotoxic drugs has been disappointing. Woodruff et al. (1967) reviewed the literature on this subject, and of 243 collected cases treated with 33 different non-hormonal agents only 10% showed signs of objective improvement: in most instances this was slight or of brief duration. Talley et al. (1969) have published their personal experience with various cytotoxic drugs against metastatic hypernephroma. Of 57 patients treated with 15 different non-hormonal compounds, chiefly alkylating agents, antimetabolites and vinblastine, objective improvement was seen in only two cases (3.50 %). Apart from these poor results, the agents employed are highly toxic and have a relatively small margin of safety.

show abstract

Section: Sexmentioning

confidence: 58%

Section: Discussionmentioning

confidence: 99%

Section: Provera Treatment Of Metastatic Renal Cancermentioning

confidence: 95%

Section: Provera Treatment Of Metastatic Renal Cancermentioning

confidence: 99%

Section: Provera Treatment Of Metastatic Renal Cancermentioning

confidence: 99%

See 3 more Smart Citations

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer

Bloom¹

1971

Br J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

Treatment of Metastatic Hypernephroma

Talley¹

1969

JAMA

View full text Add to dashboard Cite

Medroxyprogesterone acetate in the treatment of renal cell carcinoma (hypernephroma)

Samuels

Sullivan

Howe

1968

Cancer

View full text Add to dashboard Cite

Medroxyprogesterone acetate, a potent synthetic progestational steroid, was administered to 23 patients with metastatic renal cell carcinoma. Seven patients received 300 mg/d orally. Six patients received 100 mg/d intramuscularly of the commercial preparation Provera. Ten patients were given 400 mg/w intramuscularly of an investigational preparation. Twenty‐one patients completed a minimum treatment period of 6 weeks and were considered evaluable. There were one complete and two partial objective remissions to the parenteral preparations. No responses were observed with the oral preparation. The dose to response varied from 5.2 to 9.0 Gm and the duration of response from 4 to 30+ months. There did not appear to be a correlation of response with age, duration of disease, or histologic grade or cell type. A “symptom status” indicating severe disability from disease did adversely affect response. Minimal side effects were weakness in two patients, loss of libido in one male patient and minimal signs of virilism in one female patient. Eleven patients who showed progressive disease after an adequate trial of medroxyprogesterone acetate received further treatment with testosterone. There was one partial objective response of 5 months' duration. These results are superior to those obtained with chemotherapy.

show abstract

Hormone-Dependent Tumours of the Kidney

Abstract: Images Fig. 11 Figs. 12, 14 Fig. 13

Cited by 67 publications

References 37 publications

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer

Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal Cancer

Treatment of Metastatic Hypernephroma

Medroxyprogesterone acetate in the treatment of renal cell carcinoma (hypernephroma)

Contact Info

Product

Resources

About